Drug-Induced Purpura (Vascular Purpura) – Decision Support Tool
Drug-Induced Purpura (Vascular Purpura) – Decision Support
Screen • Pattern • Timing • Labs • Causality • Case Certainty • Alternatives • Management • Summary • Regulatory
1) Patient, Drug & Exposure
2) Skin Findings & Systemic Features
Suggested pattern
–
Severity tier
–
Auto based on symptoms & labs
Immediate safety
–
Updates live
Action: Stop suspected drug. Screen for bleeding risk. Order basic labs (CBC, PT/INR, aPTT, CMP, UA).
3) Labs (enter what you have)
4) Timing – TTO & Exposure at Onset
Tip: set Start, Onset, and Last dose to auto-calculate. Second box meaning — +: stopped before onset; 0: same day; −: still taking after onset.
TTO class
–
Exposure at onset
–
Risk window fit
–
Typical risk windows (quick reference)
Platelet dysfunction (NSAIDs/SSRIs/antiplatelets): days–weeks.
Anticoagulant coagulopathy (warfarin/heparin/DOAC): days–weeks (earlier if overdose).
Immune vasculitis (antibiotics/antiepileptics/diuretics): 1–8 weeks (can be months).
Heparin-induced thrombocytopenia (HIT): 5–10 days (earlier if prior exposure).
5) Causality – Quick Score
Causality: –
6) Case Definition Certainty (auto)
Certainty:
–
Based on timing, exposure, pattern, labs, dechallenge, alternatives, evidence.
0/10
7) Alternative Explanations (check any considered)
8) Management – Auto Suggestions
9) Pharmacovigilance (Regulatory Reporting)
MAH expedite rules differ by region; set if known.
What to do: —
Where to report: —
Timeline: —
Where to report: —
Timeline: —
Attach timeline, labs, biopsy, images if available.
Required case elements (quick checklist)
- Identifiable patient (initials/age/sex) and reporter (name/contact/role)
- Suspected and concomitant drugs (name, dose, route, indication, start/stop)
- Adverse event(s): description, onset date/time, seriousness, outcome
- Relevant tests/results (platelets, INR/aPTT, UA, biopsy, imaging)
- Dechallenge/rechallenge, alternative causes considered, medical history
10) Case Summary
Disclaimer: Decision support only; does not replace clinical judgment or local protocols.
